Cas:40106-14-7 2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile manufacturer & supplier

Chemical Name:2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile

CAS.NO:40106-14-7

Synonyms:2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile

Molecular Formula:C₁₁H₁₄N₂S

Molecular Weight:206.30700

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:78.05000

Exact Mass:206.08800

LogP:3.44218

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile Use and application,2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile technical grade,usp/ep/jp grade.

Related News: The CTSuccess service uses Catalent��s proprietary StartScoreTM evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics. 2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile manufacturer Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile supplier Our quality control staff then conducts analyses in the testing laboratory to examine whether the API manufactured is ultrapure. 2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 2-Amino-4,5,6,7,8,9-hexahydrocycloocta-[b]thiophene-3-carbonitrile factory In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.